Fresenius Medical Care Introduces Initial Phase of Major Share Buyback Program Worth EUR 600 Million

Fresenius Medical Care Launches Share Buyback Program

Fresenius Medical Care (FME), recognized as the leading global provider of products and services for individuals suffering from renal diseases, has taken an impactful step in capital management by announcing the initiation of its share buyback program. The program, capped at a total volume of EUR 1 billion, will commence with an initial tranche of up to EUR 600 million, set to be completed by December 15, 2026.

This share buyback initiative reflects FME's ongoing commitment to disciplined, value-centric capital management while also complementing its dividend strategy. The authorization for this operation was granted during the Company’s Annual General Meeting held on May 21, 2026. As a part of the ongoing commitment to transparency, Fresenius Medical Care will periodically update stakeholders on the progress of this buyback initiative.

Fresenius Medical Care is responsible for providing vital dialysis treatments to approximately 290,000 patients worldwide, utilizing a network of 3,539 dialysis clinics. With roughly 4.5 million patients globally in need of regular dialysis care, FME's innovative approach and robust market position underline its pivotal role in renal healthcare. Furthermore, the company is the preeminent manufacturer of essential dialysis products such as dialysis machines and dialyzers.

The decision to initiate this share buyback program comes as part of a broader strategy to optimize capital allocation, ensuring that the company continues to operate efficiently while nurturing shareholder returns. As FME remains listed both on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS), this program is set to enhance shareholder trust in the company’s future direction and stability.

As this shares buyback program rolls out, many analysts will be closely monitoring the impacts on its stock performance and overall market valuation. Such initiatives often reflect a company’s confidence in its business model and future earnings potential.

In summary, Fresenius Medical Care's move to launch the first tranche of its share buyback initiative underscores the company’s strategic financial management and dedication to delivering shareholder value, in tandem with its mission to provide essential services to those battling renal diseases.

About Fresenius Medical Care

Fresenius Medical Care is not only a leader in renal healthcare but also a significant global player that shapes the future of dialysis treatment. By leveraging advanced technologies and maintaining rigorous standards in patient care, the company continues to enhance the quality of life for millions suffering from kidney-related ailments. For more information about the company and its services, interested parties can visit Fresenius Medical Care.

Disclaimer

This announcement includes forward-looking statements which are subject to numerous risks and uncertainties. Actual results might differ materially from those described in such statements due to various factors, including business and economic conditions, regulatory approvals, and fluctuations in currency rates. Fresenius Medical Care is under no obligation to update any forward-looking statements following this press release.

Contact Information

Media Contact: Christine Peters
T +49 160 60 66 770
Email: [email protected]

Investor Relations: Dr. Dominik Heger
T +49 6172 609 2525
Email: [email protected]